|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,920.50 GBX | -1.69% |
|
-4.12% | +5.26% |
| 11:06am | Where would AI lead Pharma in the long run? |  |
| Jul. 13 | European Equities Mixed in Monday Trading; Eni to Fuel BMW Corporate Fleets With Renewable Diesel | MT |
| Market Cap | 77.82B 104B 91.32B 84.58B 147B 9,965B 150B 1,008B 395B 4,893B 391B 382B 16,900B | P/E 2026 * |
12.4x | P/E 2027 * | 11.3x |
|---|---|---|---|---|---|
| Enterprise Value | 93.11B 125B 109B 101B 176B 11,922B 180B 1,206B 473B 5,855B 468B 458B 20,219B | EV / Sales 2026 * |
2.75x | EV / Sales 2027 * | 2.53x |
| Free-Float |
92.29% | Yield 2026 * |
3.57% | Yield 2027 * | 3.76% |
Last Transcript: GSK plc
| 11:06am | Where would AI lead Pharma in the long run? | |
| Jul. 13 | GSK : UBS remains Neutral | ZD |
| Jul. 13 | GSK : JP Morgan remains a Sell rating | ZD |
| Jul. 09 | GSK : Deutsche Bank remains Neutral | ZD |
| Jul. 09 | Computacenter gets two price target hikes | AN |
| 1 day | -1.86% | ||
| 1 week | -4.12% | ||
| Current month | -3.05% | ||
| 1 month | -1.92% | ||
| 3 months | -12.31% | ||
| 6 months | +2.13% | ||
| Current year | +5.26% |
| 1 week | 1,905 |  | 1,990.5 |
| 1 month | 1,905 | | 2,049 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,288.6 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2021-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 68 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| Jun. 21 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| Jun. 07 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| May. 21 | Buy | Executive/Senior Manager | 9 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.69% | -4.12% | +34.82% | +45.47% | 104B | |
| -2.49% | -6.72% | +44.19% | +156.43% | 1,054B | |
| -2.01% | -5.35% | +61.29% | +58.22% | 621B | |
| -1.29% | -3.98% | +27.67% | +79.78% | 438B | |
| -1.12% | -3.68% | +26.89% | +20.58% | 325B | |
| -1.73% | -3.45% | +26.95% | +44.09% | 281B | |
| -1.95% | -13.92% | +15.96% | +19.76% | 262B | |
| -1.45% | -2.37% | -27.87% | -39.87% | 219B | |
| -1.56% | -3.55% | +19.52% | +56.10% | 195B | |
| -0.93% | -4.52% | +16.15% | +68.66% | 163B | |
| Average | -1.66% | -1.68% | +24.56% | +50.92% | 366.04B | |
| Weighted average by Cap. | -1.86% | -1.68% | +33.10% | +76.03% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.88B 45.33B 39.76B 36.83B 64.09B 4,339B 65.34B 439B 172B 2,131B 170B 167B 7,358B | 35.63B 47.66B 41.8B 38.72B 67.39B 4,562B 68.7B 461B 181B 2,240B 179B 175B 7,737B |
| Net income | 6.52B 8.73B 7.65B 7.09B 12.34B 835B 12.58B 84.49B 33.14B 410B 32.77B 32.05B 1,417B | 7.04B 9.42B 8.27B 7.66B 13.32B 902B 13.58B 91.25B 35.79B 443B 35.39B 34.62B 1,530B |
| Net Debt | 15.29B 20.45B 17.94B 16.61B 28.91B 1,957B 29.48B 198B 77.66B 961B 76.8B 75.12B 3,320B | 12.22B 16.35B 14.34B 13.28B 23.12B 1,565B 23.57B 158B 62.1B 769B 61.41B 60.07B 2,655B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-14 | GBX 1,920.50 | -1.69% | 3,683,364 |
| 26-07-13 | GBX 1,953.50 | -0.41% | 4,209,867 |
| 26-07-10 | GBX 1,961.50 | +0.10% | 6,366,225 |
| 26-07-09 | GBX 1,959.50 | -1.01% | 5,592,972 |
| 26-07-08 | GBX 1,979.50 | -1.17% | 4,243,789 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
